Scrip talked to Leo Pharma's new CEO Catherine Mazzacco about going up against big biopharma players in dermatology and plans to file tralokinumab in 2020.
Danish dermatology specialist Leo Pharma AS thinks it can leverage tralokinumab to become a global leader in atopic dermatitis, a big ambition given the competition in the space. The interleukin-13 blocker is a pillar of the company's expansion outside of topical psoriasis treatments, where it has a strong position.
The company is poised to file tralokinumab with the US Food and Drug Administration and the European Medicines Agency in...
Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?
Paying €90m upfront for rights to generalized pustular psoriasis drug.
Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.
Multi-blockbuster falls short in a giant cell arteritis study.
CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.
Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.
Bharatt Chowrira departs days after firm’s chair stepped down.
